AR068816A1 - Composiciones de brimonidina mejorada para el tratamiento del eritema - Google Patents
Composiciones de brimonidina mejorada para el tratamiento del eritemaInfo
- Publication number
- AR068816A1 AR068816A1 ARP080103804A ARP080103804A AR068816A1 AR 068816 A1 AR068816 A1 AR 068816A1 AR P080103804 A ARP080103804 A AR P080103804A AR P080103804 A ARP080103804 A AR P080103804A AR 068816 A1 AR068816 A1 AR 068816A1
- Authority
- AR
- Argentina
- Prior art keywords
- erythema
- patient
- treatment
- gel
- brimonidine
- Prior art date
Links
- 206010015150 Erythema Diseases 0.000 title abstract 4
- 231100000321 erythema Toxicity 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical group C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 title 1
- 229960003679 brimonidine Drugs 0.000 title 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 2
- 241001303601 Rosacea Species 0.000 abstract 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 abstract 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 abstract 2
- 201000004700 rosacea Diseases 0.000 abstract 2
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 abstract 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 abstract 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 abstract 1
- 229920002125 Sokalan® Polymers 0.000 abstract 1
- 229960001724 brimonidine tartrate Drugs 0.000 abstract 1
- 229960001631 carbomer Drugs 0.000 abstract 1
- 239000006071 cream Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- 229960005150 glycerol Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 abstract 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 abstract 1
- 229960002216 methylparaben Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960005323 phenoxyethanol Drugs 0.000 abstract 1
- 229960004063 propylene glycol Drugs 0.000 abstract 1
- 239000004408 titanium dioxide Substances 0.000 abstract 1
- 229960005196 titanium dioxide Drugs 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96719107P | 2007-08-31 | 2007-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068816A1 true AR068816A1 (es) | 2009-12-09 |
Family
ID=40407909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103804A AR068816A1 (es) | 2007-08-31 | 2008-09-01 | Composiciones de brimonidina mejorada para el tratamiento del eritema |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20090061020A1 (enExample) |
| EP (1) | EP2200617A4 (enExample) |
| JP (1) | JP2010537988A (enExample) |
| KR (1) | KR20100055453A (enExample) |
| CN (2) | CN102552112A (enExample) |
| AR (1) | AR068816A1 (enExample) |
| AU (1) | AU2008296948A1 (enExample) |
| BR (1) | BRPI0816097A2 (enExample) |
| CA (1) | CA2698680A1 (enExample) |
| MX (1) | MX2010002392A (enExample) |
| NO (1) | NO20100301L (enExample) |
| WO (1) | WO2009032223A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
| US7812049B2 (en) | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
| US20120295914A1 (en) * | 2009-05-29 | 2012-11-22 | Galderma Research & Development | Combination of adrenergic receptor agonist alpha-1 or alpha-2, preferably brimonidine with fillers, preferably hyaluronic acid |
| MX2012004890A (es) * | 2009-10-26 | 2012-09-28 | Galderma Pharma Sa | Metodos para tratar o prevenir eritema agudo. |
| EP2329849B1 (en) * | 2009-11-18 | 2015-04-29 | Galderma Research & Development | Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder |
| US8394800B2 (en) * | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
| CN103298472A (zh) * | 2010-03-26 | 2013-09-11 | 盖尔德马研究及发展公司 | 安全和有效治疗红斑的改进的方法和组合物 |
| WO2011117378A2 (en) * | 2010-03-26 | 2011-09-29 | Galderma Research & Development | Improved methods and compositions for safe and effective treatment of telangiectasia |
| FR2966366B1 (fr) * | 2010-10-21 | 2012-11-09 | Galderma Sa | Composition de gel de brimonidine |
| RU2013123043A (ru) * | 2010-10-21 | 2014-12-10 | Галдерма С.А. | Гелевая композиция для местного применения |
| ES2498217T5 (es) * | 2010-10-21 | 2018-03-19 | Galderma S.A. | Composición en forma de gel basada en brimonidina |
| US8053427B1 (en) | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
| FR2966365B1 (fr) * | 2010-10-21 | 2012-11-09 | Galderma Sa | Composition de gel topique |
| CA2827373C (en) | 2011-02-15 | 2019-05-14 | Epi Health, Llc | Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea |
| WO2013057579A2 (en) | 2011-10-19 | 2013-04-25 | Galderma Pharma S.A. | Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors |
| US9283217B2 (en) | 2011-11-10 | 2016-03-15 | Allergan, Inc. | Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
| UA109359C2 (xx) * | 2011-11-10 | 2015-08-10 | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
| FR3000397A1 (fr) | 2012-12-31 | 2014-07-04 | Galderma Res & Dev | Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee |
| FR3000398A1 (fr) * | 2012-12-31 | 2014-07-04 | Galderma Res & Dev | Combinaison de laropiprant et de brimonidine pour le traitement de la rosacee |
| FR3015288B1 (fr) | 2013-12-19 | 2016-02-12 | Galderma Res & Dev | Utilsation du naratriptan dans le traitement de la rosacee |
| CA2951725C (en) | 2014-06-11 | 2022-06-07 | Allergan, Inc. | Stabilized oxymetazoline formulations and their uses |
| EP3651767A1 (en) * | 2017-07-14 | 2020-05-20 | Galderma Research & Development | Methods and compositions for reducing side effects in chemotherapeutic treatments |
| KR20220002950A (ko) | 2019-05-01 | 2022-01-07 | 클렉시오 바이오사이언시스 리미티드 | 소양증의 치료 방법 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4285967A (en) * | 1978-06-30 | 1981-08-25 | Estee Lauder Inc. | Cosmetic preparation for reducing redness of blemishes |
| US4256763A (en) * | 1978-09-19 | 1981-03-17 | Mchugh John E | Treatment of herpes simplex infections and acne |
| GB8827968D0 (en) * | 1988-11-30 | 1989-01-05 | Boots Co Plc | Sunscreen compositions |
| US5916574A (en) * | 1996-10-09 | 1999-06-29 | Ideal Ideas, Inc. | Method of treating natural poison skin conditions |
| US6410045B1 (en) * | 1999-02-22 | 2002-06-25 | Clyde Lewis Schultz | Drug delivery system for antiglaucomatous medication |
| US6294553B1 (en) * | 2000-02-15 | 2001-09-25 | Allergan Sales, Inc. | Method for treating ocular pain |
| US20040266776A1 (en) * | 2003-06-25 | 2004-12-30 | Gil Daniel W. | Methods of preventing and reducing the severity of stress-associated conditions |
| US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| US20050020600A1 (en) * | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
| US20050276765A1 (en) * | 2004-06-10 | 2005-12-15 | Paul Nghiem | Preventing skin damage |
| CA2709199A1 (en) * | 2007-12-21 | 2009-07-02 | Galderma Laboratories, Inc. | Pre-surgical treatment |
-
2008
- 2008-08-18 US US12/193,098 patent/US20090061020A1/en not_active Abandoned
- 2008-08-29 MX MX2010002392A patent/MX2010002392A/es not_active Application Discontinuation
- 2008-08-29 AU AU2008296948A patent/AU2008296948A1/en not_active Abandoned
- 2008-08-29 CA CA2698680A patent/CA2698680A1/en not_active Abandoned
- 2008-08-29 BR BRPI0816097A patent/BRPI0816097A2/pt not_active IP Right Cessation
- 2008-08-29 CN CN201110321688XA patent/CN102552112A/zh active Pending
- 2008-08-29 CN CN200880105032A patent/CN101808645A/zh active Pending
- 2008-08-29 WO PCT/US2008/010290 patent/WO2009032223A1/en not_active Ceased
- 2008-08-29 JP JP2010522973A patent/JP2010537988A/ja not_active Abandoned
- 2008-08-29 KR KR1020107005023A patent/KR20100055453A/ko not_active Ceased
- 2008-08-29 EP EP08795728A patent/EP2200617A4/en not_active Withdrawn
- 2008-09-01 AR ARP080103804A patent/AR068816A1/es not_active Application Discontinuation
-
2010
- 2010-03-04 NO NO20100301A patent/NO20100301L/no not_active Application Discontinuation
-
2011
- 2011-10-21 US US13/278,955 patent/US20120040016A1/en not_active Abandoned
-
2012
- 2012-07-12 US US13/547,531 patent/US20120282346A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN101808645A (zh) | 2010-08-18 |
| EP2200617A1 (en) | 2010-06-30 |
| JP2010537988A (ja) | 2010-12-09 |
| NO20100301L (no) | 2010-03-25 |
| US20090061020A1 (en) | 2009-03-05 |
| CA2698680A1 (en) | 2009-03-12 |
| MX2010002392A (es) | 2010-07-28 |
| EP2200617A4 (en) | 2011-01-12 |
| CN102552112A (zh) | 2012-07-11 |
| KR20100055453A (ko) | 2010-05-26 |
| WO2009032223A1 (en) | 2009-03-12 |
| US20120040016A1 (en) | 2012-02-16 |
| BRPI0816097A2 (pt) | 2016-11-01 |
| AU2008296948A1 (en) | 2009-03-12 |
| US20120282346A1 (en) | 2012-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2553742T3 (es) | Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina | |
| ES2652595T3 (es) | Lactonas de sesquiterpeno tricíclico para el uso en el tratamiento de la obesidad y enfermedades relacionadas y condiciones tratables no terapéuticas | |
| CY1122516T1 (el) | Ετοιμες προς χρηση διατυπωσεις κετορολακης | |
| JP2010537988A5 (enExample) | ||
| MX2010002392A (es) | Composiciones de brimonidina mejoradas para tratar eritema. | |
| CY1119616T1 (el) | Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα | |
| CO6700862A2 (es) | Polipéptidos derivados de la il-2 con actividad agonista para la terapia del cáncer e infecciones crónicas. | |
| WO2009053741A3 (en) | Novel formulation | |
| TW201129368A (en) | Peptides used in the treatment and/or care of the skin, mucous membranes and/or hair and its use in cosmetic or pharmaceutical compositions | |
| MX2011008616A (es) | Peptidos utiles en el tratamiento y/o cuidado de la piel , mucosas y/o cuero cabelludo y su uso en composiciones cosmeticas o farmaceuticas. | |
| WO2008154368A3 (en) | Topical poloxamer formulations for enhancing microvascular flow: compositions and uses thereof | |
| JP2009102342A5 (enExample) | ||
| NZ605887A (en) | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain | |
| NZ581589A (en) | Solubilized sterile injectable formulation of docetaxel without Tween 80 | |
| MX358491B (es) | Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa. | |
| WO2012022478A3 (en) | Filler composition comprising beta-glucans | |
| NZ595767A (en) | Composition for the treatment of prostate cancer | |
| RU2012145616A (ru) | Усовершенствованные способы и композиции для безопасного и эффективного лечения эритемы | |
| RU2014150569A (ru) | Конъюгат фотосенсибилизатора и хитозана и его применение | |
| RU2018135973A (ru) | Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака | |
| ES2405323T3 (es) | Tratamiento de melanoma | |
| ECSP14023048A (es) | Agentes terapéuticos para administración subcutánea optimizados | |
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| SA519410993B1 (ar) | النشاط المضاد للبكتيريا لأوليجو سكاريد من جالاكتو وزيليتول في العلاجات الجلدية |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |